This month, the president and chief executive officer of Green Shield Canada, the fourth-largest private payer in Canada, hailed British Columbia’s strategy as “forward-thinking” and “essential to maximizing opportunities in healthcare.”
Earlier this year, British Columbia became the first Canadian province to mandate that patients currently taking reference biologics for rheumatology indications and for diabetes must be switched to biosimilars over a 6-month period.
The policy will affect patients covered under PharmaCare, a publicly funded national drug coverage program; in Canada, prescription drug coverage is split between public programs for those 65 or older, in long-term care, or without income, while private, employer-based coverage applies to all others.
This month, the president and chief executive officer of Green Shield Canada (GSC), the fourth-largest private payer in Canada, hailed British Columbia’s strategy as “forward-thinking” and “essential to maximizing opportunities in healthcare.”
Writing in an op-ed in The Globe and Mail, GSC’s Zahid Salman explained that, as innovative drugs, such as gene and cell therapies, enter the marketplace with ever-higher price tags, payers both public and private have had to make increasingly difficult decisions about which drugs are covered. Biosimilars, wrote Salman, represent a logical means by which to provide patients with effective care at a fraction of the price, helping to promote a sustainable healthcare system for Canadian patients.
However, the continued dominance of brand-name infliximab, Remicade, in the Canadian market after the entry of biosimilar options “paints a picture of financially interested parties driven to extreme measures to protect profits and sales, resorting to generating fear around the progress biosimilars represent.” The resulting low uptake of biosimilars, he added, has diminished the opportunity to promote sustainability without compromising patient care.
Salman writes that GSC applauds British Columbia for its decision to implement its biosimilar program, and he called on other provincial governments to take the same approach as a step toward greater healthcare sustainability.
GSC has been an early champion of biosimilars in the Canadian context; in 2016, the company started to give biosimilars preferred product listings on formularies, and in 2018, the payer launched a pilot switching program under which patients already treated with biologics were transitioned to biosimilars. The program, which was optional for GSC’s clients, has been highly successful, as reported previously, and patients were largely accepting of the switch.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.